Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Last trade$458.34
Day change-$3.98 (-0.86%)
Day range$455.24 – $464.24
Volume833,928
Market cap$250.07B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$250.07B
Price / earnings
26.63×
Price / book
17.42×
Price / sales
6.43×
EV / sales
7.48×
EV / EBITDA
17.02×
Profitability
Earnings per share
$17.36
Return on assets
9.78%
Return on equity
65.43%
Dividend yield
2.15%
Liquidity and leverage
Debt / equity
3.76×
Current ratio
1.48×
Quick ratio
1.2×
Cash ratio
0.57×
Cash flow
Price / cash flow
20.78×
Price / free cash flow
26.1×
Free cash flow
$9.58B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AMGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.37B
$10.05B
$8.62B
$9.87B
$9.56B
$9.18B
$8.15B
$9.09B
Cost of revenue
$2.79B
$2.81B
$2.74B
$2.98B
$3.08B
$3.01B
$2.97B
$3.11B
Gross profit
$7.58B
$7.24B
$5.87B
$6.89B
$6.48B
$6.17B
$5.18B
$5.97B
Selling, general and administrative
$1.68B
$1.75B
$1.6B
$1.95B
$1.72B
$1.69B
$1.69B
$1.88B
Research and development
$2.11B
$1.87B
$1.72B
$2.14B
$1.9B
$1.74B
$1.49B
$1.72B
Total operating expenses
$3.87B
$3.73B
$3.21B
$4.17B
$3.95B
$3.51B
$4B
$3.66B
Operating income
$3.71B
$3.51B
$2.67B
$2.72B
$2.53B
$2.66B
$1.18B
$2.31B
Interest expense
-$653M
-$673M
-$657M
-$653M
-$685M
-$694M
-$723M
-$747M
Income before taxes
$4.69B
$2.77B
$2.08B
$1.51B
$3.92B
$1.57B
$1.97B
$782M
Income taxes
$822M
$393M
$265M
$181M
$705M
$136M
$243M
$155M
Net income
$3.86B
$2.38B
$1.82B
$1.33B
$3.22B
$1.43B
$1.73B
$627M
Net income attributable to common shareholders
$3.86B
$2.38B
$1.82B
$1.33B
$3.22B
$1.43B
$1.73B
$627M
EBITDA
$4.83B
$4.63B
$3.78B
$3.85B
$3.83B
$4B
$2.57B
$3.71B
Basic earnings per share
$7.14
$4.40
$3.37
$2.48
$5.98
$2.66
$3.22
$1.17
Diluted earnings per share
$7.08
$4.37
$3.34
$2.45
$5.93
$2.65
$3.20
$1.15
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
The VanEck Biotech ETF (BBH) is a passively managed fund tracking the MVIS US Listed Biotech 25 Index with $521.91 million in assets and a low 0.35% expense ratio. The fund has delivered strong year-to-date returns of 31.47% but carries higher risk with a beta of 0.70 and concentrated exposure through its top 10 holdings representing 73.82% of assets. BBH holds a Zacks ETF Rank of 2 (Buy), though investors should consider alternatives like XBI and IBB.
AstraZeneca received FDA and EU regulatory approvals for Klygefa (gefurulimab), a complement C5 inhibitor for treating adults with AChR-positive generalized myasthenia gravis. The once-weekly, self-administered subcutaneous therapy showed significant improvements in daily activities versus placebo in Phase III trials. While the convenient dosing offers differentiation from AstraZeneca's existing IV therapies (Soliris and Ultomiris), Klygefa faces cannibalization risks and competition from other complement C5 inhibitors and alternative mechanism drugs.
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$2.52 per share
Declared
Oct 27, 2026
Ex-dividend
Nov 20, 2026
Pay date
Dec 11, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 21, 2026
$2.52
Sep 11, 2026
recurring
May 15, 2026
$2.52
Jun 5, 2026
recurring
Feb 13, 2026
$2.52
Mar 6, 2026
recurring
Nov 21, 2025
$2.38
Dec 12, 2025
recurring
Aug 22, 2025
$2.38
Sep 12, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.